Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) mobilization predicting 16.9 million and 19.6 million cells/kg collected in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback